Key HighlightsNanexa shares skyrocketed 122% in Friday’s opening session following announcement of a Novo Nordisk partnership.The licensing agreement carries a potential value of €1.17 billion (approximately $1.33 billion).Novo Nordisk secures worldwide exclusive access to Nanexa’s PharmaShell platform across five potential development initiatives.The collaboration focuses on treatments for obesity, type 2 diabetes, and related cardiometabolic conditions.Nanexa stands to receive low single-digit percentage royalties on worldwide commercial sales of any approved products.Shares of Nanexa experienced extraordinary gains during Friday’s early trading hours. The Swedish pharmaceutical technology firm witnessed its stock price surge more than 120% following disclosure of a substantial licensing partnership with Novo Nordisk.Nanexa AB (publ) (NANEXA.ST)News of the collaboration emerged after Thursday’s close of U.S. trading sessions. The total potential value reaches €1.17 billion, equivalent to approximately $1.33 billion.Following the announcement, Nanexa’s stock climbed to levels not witnessed in over half a decade. Market activity intensified dramatically as traders responded swiftly to the development.At the heart of this partnership lies Nanexa’s proprietary PharmaShell technology. This innovative drug delivery system employs an extremely thin coating applied to microscopic drug particles.This specialized coating regulates the timing and rate at which medication disperses throughout the body. Essentially, it functions as a precisely controlled release system operating at the molecular scale.Partnership Scope and FocusUnder this arrangement, Novo Nordisk obtains global exclusive licensing rights for PharmaShell technology across as many as five separate development initiatives. The primary therapeutic areas include obesity management, type 2 diabetes treatment, and additional cardiometabolic disorders.Both organizations are pursuing the development of extended-release injectable medications. The objective involves transitioning from current weekly administration schedules to monthly or even quarterly injection intervals.Reducing injection frequency could significantly simplify treatment adherence for individuals dealing with long-term health conditions. This convenience factor represents a core value proposition of the collaboration.Novo Nordisk assumes responsibility for all worldwide development activities and commercial launch strategies associated with this agreement. Nanexa’s contribution remains focused on providing its core technological platform.Financial Terms and StructureThe €1.17 billion total encompasses €615 million allocated to initial payments combined with achievement-based development and regulatory approval milestones. The remaining portion ties directly to commercial sales performance targets.Additionally, Nanexa will receive ongoing royalty payments based on worldwide net revenues from any commercialized products emerging from this collaboration. These royalty rates fall within the low single-digit percentage range.This framework represents a standard approach in pharmaceutical licensing arrangements. The technology provider receives guaranteed immediate compensation, followed by smaller ongoing revenue shares contingent upon successful market entry and sales performance.According to Nanexa’s official announcement, the collaboration merges its atomic layer deposition-based drug delivery system with Novo Nordisk’s extensive expertise in developing obesity and diabetes therapeutics. This characterization appeared in the company’s formal press statement.By 0723 GMT on Friday, Nanexa shares continued trading approximately 122% higher. In contrast, Novo Nordisk stock showed a relatively modest 1% increase in response to the partnership announcement.The post Nanexa (NANEXA) Stock Rockets 122% Following Massive Novo Nordisk Partnership appeared first on Blockonomi.